SEP 29, 2015
Provista Diagnostics Offers Hope for the Early Detection of Breast Cancer in Women with Dense Breasts
Data presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium received overwhelming support from Key Opinion Leaders involved in the clinical trials
New York, NY – September 29, 2015 – Provista Diagnostics, Inc. today announced that the data from two prospective, randomized, multi-center clinical studies, evaluating a novel blood- based combinatorial protein biomarker assay, received overwhelming support from Key Opinion Leaders at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, held September
Read MoreSEP 23, 2015
Provista Diagnostics to Present New Clinical Data at the 2015 American Society of Clinical Oncology Breast Cancer Symposium
New York, NY – September 23, 2015 – Provista Diagnostics, Inc., a privately-held molecular diagnostics
SEP 21, 2015
Provista Diagnostics Announces Reelection of the Company’s Board of Directors
All Director Candidates Elected by Overwhelming Majority
New York, NY – September 21, 2015 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic, and monitoring tests designed to address
AUG 13, 2015
Provista Diagnostics, Inc. Completes Enrollment of the 2nd Cohort of its 002 Prospective, Multi-Center, Randomized Trial Utilizing the Provista Biomarker Assay to Aid in the Detection of Breast Cancer
New York, NY – August 13, 2015 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company developing and commercializing a new
AUG 4, 2015
Provista Diagnostics Announces the Closing of $6.0 Million Financing
New York, NY – August 4, 2015 – Provista Diagnostics, Inc., a privately held molecular diagnostics company headquartered in New York, today announced the closing of $6.0 million of Series A-2 Preferred financing. All of the
MAR 17, 2015
Provista Diagnostics Announces the Closing of $3.9 Million Financing
New York, NY – March 17, 2015 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company headquartered in New York, today announced the closing of $3.9 million of Series A-1 Preferred financing. All of the funds
MAR 09, 2015
Provista Diagnostics Presents Key Clinical Studies at The 2015 Miami Breast Cancer Conference®
New York, NY – March 9, 2015 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on
DEC 10, 2014
Provista Diagnostics to Present Data from a Prospective Clinical Trial at the 2014 San Antonio Breast Cancer Symposium.
Data Highlights the Role of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Benign from Invasive Breast Lesions
New York, NY – December 10, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on
DEC 05, 2014
Provista Diagnostics’ Blood-based Diagnostic Featured in Oncology & Hematology Review
Highlights the Potential of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Improve Early Detection of Breast Cancer in conjunction with standard imaging practices
New York, NY – December 5, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers, today announced that its blood-based diagnostic for the early detection of breast cancer was featured in the 2014 Fall edition of Oncology & Hematology Review in an article titled, “Potential Use of Biomarkers to Augment Clinical Decisions for the Early Detection of Breast Cancer.”
Read MoreNOV 10, 2014
Provista Diagnostics Accepted for a Late-Breaking Data Presentation at the 2014 San Antonio Breast Cancer Symposium
Data Explores the Ability of Serum Protein Biomarkers in Conjunction with Tumor Associated Autoantibodies to Distinguish Between Benign and Invasive Breast Lesions
New York, NY – November 10, 2014 – Provista Diagnostics, Inc., a privately-held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women’s cancer, such as breast and gynecologic cancers, today announced acceptance of a late-breaking poster presentation at the 2014 San Antonio Breast Cancer Symposium taking place December 9-13, 2014 in San Antonio, Texas.
Read More
